Suppr超能文献

EGFR野生型和突变型非小细胞肺癌患者早期和晚期脑转移的影像学特征及生存情况

Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.

作者信息

Yuan Ren, Yamada Andrew, Weber Britta, Ho Cheryl

机构信息

Department of Diagnostic Imaging, BC Cancer Agency, Vancouver, BC, Canada.

Department of Medical Oncology, BC Cancer Agency, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

出版信息

J Neurooncol. 2016 May;127(3):525-33. doi: 10.1007/s11060-016-2057-5. Epub 2016 Jan 16.

Abstract

Brain metastasis (BM) in NSCLC is a negative prognostic indicator. In the era of EGFR mutations we evaluated the difference between early (≤6 months from diagnosis) versus late BM (>6 months), in EGFR wild type (WT) and mutant (MT) NSCLC patients with respect to radiographic patterns and overall survival (OS). A retrospective study was conducted of referred patients with non-squamous NSCLC with known EGFR mutation status treated for BM from Mar 2010-Dec 2012. Radiographic patterns, treatment and survival were collected. 430 patients were identified: 327 WT (207 early vs. 120 late) and 103 MT (65 early vs. 38 late). Early and late BM radiographic patterns were similar in EGFR WT patients. In EGFR MT there was a trend towards multiple lesions in the late compared to early BM group. OS from initial diagnosis early BM: WT 7.1 months versus MT 19.9 months (p < 0.001). OS from initial diagnosis late BM: WT 24.9 months versus MT 25.6 months (p = 0.51). In multivariate analysis chemotherapy, single lesion and late BM were associated with better survival in WT patients whereas age, and systemic treatment but not BM timing or single lesion were predictive of better outcomes in MT patients. In early BM, EGFR MT have an OS comparable to late BM. In contrast, early BM EGFR WT have a significantly reduced survival compared to late BM. The positive outcome in EGFR MT may be secondary to systemic control and EGFR TKI penetrance across the blood brain barrier.

摘要

非小细胞肺癌(NSCLC)脑转移(BM)是一个不良预后指标。在表皮生长因子受体(EGFR)突变时代,我们评估了EGFR野生型(WT)和突变型(MT)NSCLC患者中早期(诊断后≤6个月)与晚期BM(>6个月)在影像学特征和总生存期(OS)方面的差异。对2010年3月至2012年12月期间因BM接受治疗且已知EGFR突变状态的非鳞状NSCLC转诊患者进行了一项回顾性研究。收集了影像学特征、治疗情况和生存数据。共确定了430例患者:327例WT(207例早期与120例晚期)和103例MT(65例早期与38例晚期)。EGFR WT患者的早期和晚期BM影像学特征相似。在EGFR MT中,与早期BM组相比,晚期有多发灶的趋势。从初始诊断开始的早期BM的OS:WT为7.1个月,而MT为19.9个月(p<0.001)。从初始诊断开始的晚期BM的OS:WT为24.9个月,而MT为25.6个月(p=0.51)。多因素分析显示,化疗、单发病灶和晚期BM与WT患者更好的生存相关,而年龄和全身治疗而非BM时间或单发病灶可预测MT患者的更好结局。在早期BM中,EGFR MT的OS与晚期BM相当。相比之下,早期BM的EGFR WT与晚期BM相比生存显著降低。EGFR MT的良好结局可能继发于全身控制以及EGFR酪氨酸激酶抑制剂(TKI)穿过血脑屏障的渗透率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验